Table 1. Study practices (806) compared with all other practices in England (7,439): characteristics drawn from QOF data set 2010.
| Practice characteristic | Mean (s.d.) | Difference between means (± 95% CI) |
|---|---|---|
|
Practice list size | ||
| Study | 6,517 (3,780) | −166 (−133.1 to 444.7) |
| England | 6,683 (4,228) | |
|
Males (%) | ||
| Study | 50.7 (2.6) | 0.4 (0.2–0.6) |
| England | 50.3 (2.9) | |
|
Patients aged 45+ (%) | ||
| Study | 39.3 (9.5) | −1.2 (−2.0 to -0.6) |
| England | 40.5 (10.1) | |
|
Patients aged 45–64 (%) | ||
| Study | 24.5 (4.9) | −0.6 (−1.0 to -0.3) |
| England | 25.1 (4.9) | |
|
Patients aged 65–74 (%) | ||
| Study | 7.8 (2.6) | −0.3 (−0.5 to −0.1) |
| England | 8.1 (3.0) | |
|
Patients aged 75+ (%) | ||
| Study | 7.0 (2.7) | −0.3 (−0.5 to−0.1) |
| England | 7.3 (3.8) | |
|
Deprivation score | ||
| Study | 33.8 (17.6) | 8.0 (6.6–9.2) |
| England | 25.8 (17.2) | |
|
PCT cost of LABA+ICS/patient (£) | ||
| Study | 9.60 (2.00) | 0.57 (−0.77 to 1.90) |
| England | 9.03 (2.54) | |
|
PCT cost of LAMA/patient (£) | ||
| Study | 2.64 (0.67) | 0.26 (−0.19 to 0.71) |
| England | 2.38 (0.85) | |
|
Diagnosed COPD prevalence (%) | ||
| Study | 1.93 (0.88) | 0.26 (0.19–0.32) |
| England | 1.67 (0.97) | |
|
QOF
points/available | ||
| Study | 0.948 (0.04) | 0.001 (−0.005 to 0.003) |
| England | 0.947 (0.05) | |
|
COPD points/available | ||
| Study | 0.981 (0.06) | 0.008 (0.003–0.012) |
| England | 0.973 (0.10) | |
|
Smoking points/available | ||
| Study | 0.994 (0.04) | 0.002 (−0.0036 to 0.0004) |
| England | 0.992 (0.03) | |
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; LABA+ICS, combined inhaled long-acting β2-agonist and corticosteroid; LAMA, long-acting anti-muscarinic; PCT, Primary Care Trust; QOF, Quality and Outcomes Framework.